阅读说明：本技术 6-o-烟酰半枝莲素c用于制备抗绒毛膜癌药物的用途 (Application of 6-O-nicotinoyl heminellin C in preparation of anti-choriocarcinoma drug ) 是由 蔡凤梅 陈亮 于 2020-07-01 设计创作，主要内容包括：本发明公开了6-O-烟酰半枝莲素C用于制备抗绒毛膜癌药物的用途。本发明发现,6-O-烟酰半枝莲素C具有优异的抗绒毛膜癌的作用,6-O-烟酰半枝莲素C可以抑制绒毛膜癌细胞的的增殖,而且6-O-烟酰半枝莲素C的这种抑制作用随着药物作用浓度的升高以及药物作用时间的延长而增强。(The invention discloses application of 6-O-nicotinoyl hemidendron C in preparing an anti-choriocarcinoma medicament. The invention discovers that 6-O-nicotinoyl-hemiliensinine C has excellent effect of resisting choriocarcinoma, the 6-O-nicotinoyl-hemiliensinine C can inhibit proliferation of choriocarcinoma cells, and the inhibition effect of the 6-O-nicotinoyl-hemiliensinine C is enhanced along with the increase of the action concentration of a medicament and the prolonging of the action time of the medicament.)

1.6-O-nicotinoyl hemidendron C for preparing anti-choriocarcinoma medicine.

2. The pharmaceutical use according to claim 1, wherein the anti-choriocarcinoma comprises inhibition of proliferation of choriocarcinoma cells.

Technical Field

The invention belongs to the field of medicines, and particularly relates to application of 6-O-nicotinoyl hemidendron C in preparation of a choriocarcinoma resistant medicine.

Background

Choriocarcinoma is a highly malignant tumor secondary to hydatidiform mole, miscarriage, or after term delivery. A few of them occur after ectopic pregnancy, and are usually women of childbearing age. Ovarian cancer, which occasionally occurs in an unmarried woman, is known as primary choriocarcinoma. The application of the chemical drug treatment obviously improves the prognosis of choriocarcinoma.

6-O-nicotinoyl scutellarin C (CAS: 1015776-92-7) is a natural product existing in Scutellaria barbata and other plants, and is found to have various pharmacological activities in earlier researches. There is currently no application for the treatment of choriocarcinoma.

Disclosure of Invention

The invention aims to overcome the defects of the prior art and provides the application of 6-O-nicotinoyl hemimellea C in preparing the anti-choriocarcinoma medicament for treating choriocarcinoma.

The technical scheme for realizing the purpose of the invention is as follows:

the 6-O-nicotinoyl hemiliensinine C is used for preparing the anti-choriocarcinoma drug.

Further, the anti-choriocarcinoma comprises inhibiting proliferation of choriocarcinoma cells.

The beneficial technical effects are as follows:

the invention discovers that 6-O-nicotinoyl-hemiliensinine C has excellent effect of resisting choriocarcinoma, the 6-O-nicotinoyl-hemiliensinine C can inhibit proliferation of choriocarcinoma cells, and the inhibiting effect of the 6-O-nicotinoyl-hemiliensinine C is enhanced along with the increase of the action concentration of the medicine and the prolonging of the action time of the medicine.

Drawings

FIG. 1 shows that 6-O-nicotinoyl-heminellin C has 24, 48 and 72h inhibition rates under different concentrations, and the inhibition effect of 6-O-nicotinoyl-heminellin C on human choriocarcinoma cells is enhanced along with the increase of the action concentration of the medicament and the prolongation of the action time of the medicament, so that obvious time-dependent effect and dosage-dependent effect are presented.

Detailed Description

The following examples illustrate the essence of the present invention, but should not be construed as limiting the scope of the present invention.

First, experimental material

Human choriocarcinoma JAR cells were purchased from ATCC.

Fetal bovine serum, RPMI1640 medium was purchased from Gibco, USA.

Tetrazolium blue (MTT) was purchased from Biotrin, usa, and dimethyl sulfoxide (DMSO) was purchased from Sigma, usa.

6-O-nicotinoyl scutellarin C was purchased from Chenguan Biotech limited of Baoji city and has HPLC purity of 98%.

Second, Experimental methods

1. Cell culture

Human choriocarcinoma JAR cells were cultured in RPMI1640 containing 10% fetal bovine serum at 37 ℃ under 5% CO₂Culturing in an incubator, carrying out passage once for 2-3 d, and taking cells in logarithmic growth phase for MTT test.

2. Test grouping

Divided into a control group, a low concentration group, a medium concentration group and a high concentration group.

3. MTT assay

Collecting human choriocarcinoma JAR cells in logarithmic growth phase, preparing into cell suspension with RPMI1640 culture medium containing 10% fetal calf serum, inoculating into 96-well plate with 5000 cells per well, standing at 37 deg.C and 5% CO₂And (3) carrying out conditioned culture, after 24h, replacing the control group with an RPMI1640 culture medium containing 10% fetal calf serum for continuous culture, replacing the low-concentration group, the medium-concentration group and the high-concentration group with an RPMI1640 culture medium containing 2.5, 5 and 10 mu M6-O-nicotinoyl hemiliensin C and 10% fetal calf serum for continuous culture, after 24, 48 and 72h of continuous culture, adding 20 mu L of sterile MTT solution (5mg/mL) into each well, after 4h of culture, abandoning supernatant, adding 150 mu L of DMSO into each well, shaking to dissolve crystals, measuring the absorbance value (OD) of each well by using an enzyme labeling instrument at a wavelength of 570nm, and calculating the proliferation inhibition rate of 6-O-nicotinoyl hemiliensin C acting on human choriocarcinoma JAR cells at different times according to the following formula, wherein the inhibition rate is OD control-OD medicament/OD × 100%.

3. Data analysis

SPSS15.0 statistical software is adopted to carry out one-factor variance analysis, 5 multiple holes are respectively arranged, all experimental data are represented by mean values +/-standard difference, and P < 0.05 represents that the difference is obvious.

Third, experimental results

As shown in tables 1 to 3 and FIG. 1, 6-O-nicotinoyl-barbadosnut C can significantly inhibit the proliferation of choriocarcinoma cells, and the inhibitory effect of 6-O-nicotinoyl-barbadosnut C is enhanced with the increase in the concentration of the drug and the increase in the duration of the drug. Therefore, 6-O-nicotinoyl-barbadosnut C has an excellent anti-choriocarcinoma effect.

TABLE 1 inhibition rate of 6-O-nicotinoyl hemiliensinine C on 24h at different concentrations

TABLE 2 inhibition rate of 6-O-nicotinoyl-barbadostachyin C at different concentrations for 48h

TABLE 3 inhibition rate of 6-O-nicotinoyl-hemiliensinine C for 72h at different concentrations

The test results show that the 6-O-nicotinoyl heminellin C has the prospect of being developed into a drug for resisting human choriocarcinoma.